NCT07565285
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07565285
Title The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma (INFLECTION-003)
Acronym INFLECTION-003
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Primmune Therapeutics, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries AUS

Facility Status City State Zip Country Details
Calvary Mater Newcastle RECRUITING Waratah New South Wales 2298 Australia Details
Cairns And Hinterland Hospital And Health Service NOT_YET_RECRUITING Cairns Queensland 4870 Australia Details
Gallipoli Medical Research NOT_YET_RECRUITING Greenslopes Queensland 4120 Australia Details
Princess Alexandra Hospital NOT_YET_RECRUITING Woolloongabba Queensland 4102 Australia Details
Peter MacCallum Cancer Centre RECRUITING Melbourne Victoria 3000 Australia Details
One Clinical Research Pty Ltd RECRUITING Nedlands Western Australia 6009 Australia Details
Sir Charles Gairdner Hospital NOT_YET_RECRUITING Nedlands Western Australia 6009 Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field